Tiakis Biotech is preparing for a Phase 2 U.S. trial of tiprelestat for PAH after completing a data package required for ...

This holiday season, columnist Anna Jeter is searching for some silver linings in her life and to try to be grateful, despite ...

A mouse study shows overproduction of the naturally occurring hormone adrenomedullin reduced lung injury and PH in ...

Merck Canada said it has successfully completed negotiations on its PAH therapy Winrevair with the pan‑Canadian ...

Scientists identified two proteins as biomarkers of CTEPH severity and progression, a discovery that could pave the way for ...

Pulmonary hypertension (PH) is a rare but life-threatening disease that affects the pulmonary arteries, making them narrow and thick. The vessels, which are responsible for transporting blood from the ...

The American Lung Association is the leading organization working to save lives by improving lung health and preventing lung disease through education, advocacy and research.

Merck plans a Phase 3 trial of Winrevair after a Phase 2 study testing it in CpcPH due to HFpEF hit its main goal.

Low oxygen levels, or hypoxia, in early life impaired lung blood vessel growth, leading to severe pulmonary hypertension in a mouse model.

My mom was quick to share her dream with me from the night before when I came downstairs for breakfast on a recent morning. In the dream, I was still living with pulmonary hypertension (PH), and we ...

Researchers have identified distinct genetic changes tied to the severity of idiopathic pulmonary arterial hypertension (IPAH) and chronic thromboembolic pulmonary hypertension (CTEPH). Data showed ...